Compare · ALMR vs WAT
ALMR vs WAT
Side-by-side comparison of Alamar Biosciences Inc. (ALMR) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ALMR and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $35.87B, about 25.2x ALMR ($1.42B).
- Over the past year, ALMR is down 10.3% and WAT is up 4.6% - WAT leads by 14.9 points.
- WAT has been more active in the news (8 items in the past 4 weeks vs 1 for ALMR).
- WAT has more recent analyst coverage (25 ratings vs 5 for ALMR).
- Company
- Alamar Biosciences Inc.
- Waters Corporation
- Price
- $19.91-3.04%
- $364.85-0.14%
- Market cap
- $1.42B
- $35.87B
- 1M return
- -15.74%
- +4.14%
- 1Y return
- -10.30%
- +4.64%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2026
- 1995
- News (4w)
- 1
- 8
- Recent ratings
- 5
- 25
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest ALMR
- Alamar Biosciences Makes Home-Collected Fingerstick Samples Compatible with Ultra High-Sensitivity, Multiplex Proteomics
- Analyst initiated coverage on Alamar Biosciences with a new price target
- BofA Securities initiated coverage on Alamar Biosciences with a new price target
- TD Cowen initiated coverage on Alamar Biosciences with a new price target
- Leerink Partners initiated coverage on Alamar Biosciences with a new price target
- Stifel initiated coverage on Alamar Biosciences with a new price target
- SEC Form 10-Q filed by Alamar Biosciences Inc.
- Alamar Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Alamar Biosciences Reports First Quarter 2026 Financial Results
- Alamar Biosciences to Participate in BofA Securities 2026 Healthcare Conference
Latest WAT
- Waters Launches Industry-First Reversed-Phase Bioseparation Columns to Deliver Up to 3x Faster GLP-1 Characterization and 2x Faster LNP Component Analysis
- Waters Announces FDA 510(k) Clearance of BD BACTEC FXI Culture System, Enabling Broader Access to Bloodstream Infection Diagnostics
- Wolfe Research resumed coverage on Waters with a new price target
- Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research
- Waters Unveils Cyclic IMS P20 MS: The New Benchmark in Structural and Spatial Omics
- SEC Form SD filed by Waters Corporation
- SEC Form 8-K filed by Waters Corporation
- Waters Corporation to Present at the Jefferies Global Healthcare Conference
- SVP & Chief Financial Officer Chaubal Amol covered exercise/tax liability with 239 shares, decreasing direct ownership by 3% to 7,623 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 10-Q filed by Waters Corporation